Literature DB >> 30269617

Recent advances in our understanding of the pathogenesis of juvenile idiopathic arthritis and their potential clinical implications.

Jing Yao Leong1, Yeo Joo Guan1,2,3, Salvatore Albani1,2,3, Thaschawee Arkachaisri2,3.   

Abstract

INTRODUCTION: Juvenile idiopathic arthritis (JIA) comprises systemic and non-systemic forms of chronic childhood arthritis diagnosed prior to age 16. Significant improvement in treatment outcomes has been witnessed since the introduction of biologics. In particular, advances in research in the area of multidimensional interrogation and network analysis have facilitated understanding of the complex cacophony of components orchestrating disease immunopathogenesis. Areas covered: In this review, we will examine the scientific advances that have augmented our understanding of JIA pathogenesis, focusing on the progress made in systemic, poly, and oligo JIA in four major aspects: (a) unraveling the pathogenic mechanisms, (b) disease classification, (c) therapeutic selection, and (d) decision for withdrawal of medications after achieving remission. Expert commentary: Dysregulation of innate immune cell physiology and function in sJIA will be highlighted. MicroRNAs contribute to monocyte/macrophage polarization with resulting consequences on macrophage activation syndrome development. The involvement of neutrophils, a major source of S100A8/9/12, in the active inflammatory phase of sJIA is compelling. In non-sJIA, circulating CD4 subsets in T effector and regulatory compartments possessing a strong synovial T-cell receptor coverage and disease activity correlation, acted as an accessible reservoir of pathogenic cells exploitable for clinical management.

Entities:  

Keywords:  JIA; Juvenile idiopathic arthritis; immunopathogenesis; pathogenesis; precision medicine

Mesh:

Substances:

Year:  2018        PMID: 30269617     DOI: 10.1080/1744666X.2018.1529757

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  4 in total

Review 1.  Research progress in drug therapy of juvenile idiopathic arthritis.

Authors:  Wen-Jia Zhao; Jiang-Hong Deng; Cai-Feng Li
Journal:  World J Pediatr       Date:  2022-04-01       Impact factor: 2.764

2.  Novel biomarkers for early targeted and individualized treatment in Juvenile Idiopathic Arthritis.

Authors:  Artemis Koutsonikoli; Anna Taparkou; Polyxeni Pratsidou-Gkertsi; Vassiliki Sgouropoulou; Theodoros Dimitroulas; Maria Trachana
Journal:  Mediterr J Rheumatol       Date:  2020-06-01

3.  Immunome perturbation is present in patients with juvenile idiopathic arthritis who are in remission and will relapse upon anti-TNFα withdrawal.

Authors:  Jing Yao Leong; Phyllis Chen; Joo Guan Yeo; Fauziah Ally; Camillus Chua; Sharifah Nur Hazirah; Su Li Poh; Lu Pan; Liyun Lai; Elene Seck Choon Lee; Loshinidevi D/O Thana Bathi; Thaschawee Arkachaisri; Daniel Lovell; Salvatore Albani
Journal:  Ann Rheum Dis       Date:  2019-09-20       Impact factor: 19.103

Review 4.  Targeting CCN Proteins in Rheumatoid Arthritis and Osteoarthritis.

Authors:  Iona J MacDonald; Chien-Chung Huang; Shan-Chi Liu; Yen-You Lin; Chih-Hsin Tang
Journal:  Int J Mol Sci       Date:  2021-04-21       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.